|
 |
| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 23
| Issue : 1 | Page : 135-138 |
|
|
Tacrolimus ointment for treatment of vernal keratoconjunctivitis
Abdulrahman M Al-Amri1, Aleem Gulzar Mirza2, Ahmed Mossa Al-Hakami3
1 Department of Ophthalmology, College of Medicine, King Khaled University, Abha, Saudi Arabia
2 Department of Ophthalmology, Aseer Central Hospital, Abha, Saudi Arabia
3 Department of Microbiology and Clinical Parasitology, College of Medicine, King Khaled University, Abha, Saudi Arabia
| Date of Web Publication | 4-Jan-2016 |
Correspondence Address:
Abdulrahman M Al-Amri
Department of Ophthalmology, College of Medicine, King Khaled University, P. O. Box 641, Abha 61421
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-9233.164616
 Abstract | | |
Purpose: To evaluate the safety and efficacy of tacrolimus 0.1% ointment for the treatment of refractory vernal keratoconjunctivitis (VKC).
Materials and Methods: This prospective, nonrandomized case series enrolled 20 patients (40 eyes) with severe VKC, who were treated with tacrolimus 0.1% ointment. The mean age of the patients was 18.25 ± 4.2 years (range, 9–31 years). Each patient completed a follow-up period of at least 24 months. The main outcome measure was the clinical response to treatment.
Results: after starting treatment with topical tacrolimus. Treatment was gradually reduced, with increasing intervals between applications. VKC recurred in all patients who attempted to discontinue treatment. No additional medications were required and no significant changes in visual acuity or refraction were documented. Five patients discontinued treatment due to a severe burning sensation and were excluded from the study.
Conclusions: Tacrolimus, 0.1% ointment, is a safe and effective treatment for VKC refractory to standard treatment and may be used as a substitute for steroid treatments used to controlled disease activity. However, adverse effects could cause poor patient compliance.
Keywords: Allergy, Tacrolimus, Vernal Keratoconjunctivitis
How to cite this article:
Al-Amri AM, Mirza AG, Al-Hakami AM. Tacrolimus ointment for treatment of vernal keratoconjunctivitis. Middle East Afr J Ophthalmol 2016;23:135-8 |
How to cite this URL:
Al-Amri AM, Mirza AG, Al-Hakami AM. Tacrolimus ointment for treatment of vernal keratoconjunctivitis. Middle East Afr J Ophthalmol [serial online] 2016 [cited 2022 Aug 19];23:135-8. Available from: http://www.meajo.org/text.asp?2016/23/1/135/164616 |
| Introduction | |  |
Vernal keratoconjunctivitis (VKC) is a bilateral, chronic inflammation of the conjunctiva that predominantly affects children between 3 and 16 years of age. It usually resolves at puberty, but can continue into adulthood. Although the name vernal suggests a seasonal, springtime occurrence, this allergic condition frequently persists throughout the year and usually increases in intensity in warmer weather.[1],[2] Patients with VKC experience significant morbidity.[3] Symptoms include intense itching, tearing, mucous secretions, and photophobia.[4] Common conjunctival signs of VKC are hyperemia, papillary hypertrophy, giant papillae, discharge, and trantas dots.[5]
Tacrolimus is a strong, nonsteroidal immune suppressant isolated from Streptomyces tsukubaensi.[6] It binds to FK506-binding proteins in T-lymphocytes and inhibits calcineurin activity. Calcineurin inhibition suppresses dephosphorylation of the nuclear factor of activated T-cells and its transfer into the nucleus, which suppresses the formation of T-helper (Th) 1 (interleukin [IL]-2, interferon γ) and Th2 cytokines (IL-4, IL-5).[7] Tacrolimus also inhibits histamine release from mast cells, which is thought to alleviate allergic symptoms.[8] Tacrolimus is up to 100 times more potent than cyclosporine.[9],[10],[11] Tacrolimus ointment is used widely for the treatment of atopic dermatitis. Topical tacrolimus (0.02–0.1%) has also been used to treat giant papillary conjunctivitis, atopic keratoconjunctivitis (AKC), and VKC [12],[13],[14],[15],[16],[17],[18] with good results. Furthermore, a tacrolimus 0.1% ophthalmic suspension has been used for the treatment of AKC and VKC with only 4 weeks of follow-up.[18]
The purpose of this study was to evaluate the long-term clinical outcomes of tacrolimus ointment as a treatment for refractory VKC.
| Materials and Methods | | |
This prospective, nonrandomized, noncontrolled case series study followed 40 eyes from 20 patients with active VKC refractory to conventional treatment. The Institutional Review Board of King Khalid University, Abha, Saudi Arabia approved the study protocol. Patients were recruited from Magrabi Aseer Hospital after written informed consent was obtained. This study adhered to the tenets of the declaration of Helsinki.
All study participants had active disease and were steroid dependent, despite treatment with cyclosporine or conventional treatments such as antihistamines, mast-cell stabilizers, topical nonsteroidal anti-inflammatory drugs, and topical steroids. Exclusion criteria were coexisting conjunctival disorders, chemical injury, Stevens-Johnson syndrome, corneal diseases, uveitis, ocular infections, and contact lens use, a history of systemic nonsteroidal anti-inflammatory or immunosuppressive drug use, and ocular surgery in the previous 3 months. VKC was diagnosed by (1) symptoms (chronic, bilateral itching, redness); and (2) signs (trantas dots, papillae on the upper tarsal conjunctiva, corneal erosions). Complete ophthalmic examinations were performed, including best spectacle-corrected visual acuity (BSCVA), slit-lamp biomicroscopy, fluorescein staining, fundoscopy, and applanation tonometry.
Study participants discontinued all medications, 1-week before beginning treatment. All participants were instructed to apply tacrolimus 0.1% dermatologic ointment (Astellas Toyama, Toyama, Japan) to the inferior conjunctival fornix of each eye. The dose for severe AKC was once daily for 1-month followed by a taper to every other day for 1-week; then twice a week for 1-week; then once a week. The dose for moderate AKC was once every other day for 1-month followed by a taper to twice a week for 1-week; then once a week. The dose for mild AKC was twice a week for the 1st month and then once a week. During treatment, patients returned for evaluation after 1-week, 4 weeks, 6 weeks, and then every 6 months. The primary efficacy endpoint was change from baseline with topical tacrolimus treatment. Main outcomes were graded by severity of signs and symptoms at baseline (before treatment) and at each visit using a 4-grade scale (0 = no symptoms; 1 = mild; 2 = moderate; 3 = severe) [Table 1]. Symptoms included itching, redness, foreign body sensation. Signs included conjunctival hyperemia, papillary hypertrophy of the superior tarsal conjunctiva, trantas dots, and superficial punctuate keratopathy.
All data were analyzed using SPSS (IBM Corp, New York, NY, USA). Analysis of variance and the Wilcoxon test were to analyze changes in the mean scores of signs and symptoms following treatment with topical tacrolimus 0.1% ointment. P ≤ 0.05 was considered statistically significant.
| Results | | |
Forty eyes from 20 patients (18 males) with bilateral VKC (mean ± standard deviation duration; 61.25 ± 4.24 months) were included in this study. The mean age was 23.14 ± 3.8 years [Table 2]. All patients had active, perennial, symptomatic disease that was refractory to medication, including antihistamines, mast-cell stabilizers, topical cyclosporine, and steroids. Itching was the most prominent symptom (17/20); other complaints included redness and foreign body sensation. All eyes had lid thickening, conjunctival hyperemia, and papillary conjunctivitis, and 10% of patients had a history of atopy. After starting treatment with tacrolimus 0.1% ointment, patients were followed for a mean duration of 27.20 ± 0.70 months [Table 3]. | Table 3: Mean score of symptoms in patients with VKC before and after treatment with topical tacrolimus 0.1% ointment
Click here to view |
There were significant improvements in the clinical signs and symptoms of disease after starting treatment with tacrolimus [Table 4]. Itching was the first symptom to decrease. At baseline, 17 of 20 patients complained of itching (14 severe, 3 moderate), however, after 1-week of treatment, all patients improved. After 6 weeks, all patients achieved complete resolution of their symptoms of itching [Table 3]. At the end of the follow-up period, all patients remained asymptomatic but continued to apply topical tacrolimus ointment. No additional medications, such as mast cell stabilizers, topical cyclosporine, or steroids, were required to provide additional relief. | Table 4: Mean score of objective signs in patients with VKC before and after treatment with topical 0.1% tacrolimus ointment
Click here to view |
Prior to treatment, conjunctival hyperemia was present in 38 eyes (28 severe, 6 moderate, 4 mild). Conjunctival hyperemia was completely resolved in 36/40 eyes, 6 weeks after the initiation of treatment.
Improvement in conjunctival papillary hypertrophy was seen in 20 eyes, 6 weeks after starting treatment. After 3 months, 8 patients had only mild papillary hypertrophy. Twenty-one eyes that had moderate or severe lid thickening at baseline showed improvements in clinical signs, 6 weeks after starting treatment. All patients (20/40 eyes) with moderate or severe corneal punctate epithelial erosions showed improvement 8 weeks after starting treatment. All these eyes had mild corneal punctate epithelial erosions after 2 months of treatment which completely resolved at the last follow-up visit [Table 4]. At the end of the study, all patients with VKC were still using tacrolimus ointment due to recurrence while attempting to discontinue treatment. However, these patients experienced a dramatic improvement when they resumed a once-weekly tacrolimus treatment regimen. Five patients discontinued treatment because of a severe burning sensation and were excluded from the study. BSCVA and refraction remained unchanged throughout the follow-up period.
| Discussion | | |
Tacrolimus is an effective agent for the management of patients with AKC and VKC who are refractory to conventional medications, including topical cyclosporine.[12],[13],[14],[15],[16],[17],[18] In our study, topical tacrolimus achieved good results in the management of severe cyclosporine-resistant VKC. Previously, Daniell et al.[19] reported that 0.05% topical cyclosporine was not an effective steroid-sparing agent in steroid-dependent allergic conjunctivitis. Consistent with previous reports, almost all patients in our study showed dramatic improvements in inflammatory signs and symptoms without significant adverse effects. Although none of our patients required additional medications, including topical steroids, for additional relief, long-term use of tacrolimus was needed to control disease recurrence. In a multicenter, randomized clinical trial, Ohashi et al.[17] used tacrolimus 0.1% ophthalmic suspension twice daily for 4 weeks in 21 patients with AKC and 7 patients with VKC and compared to the outcome to a placebo group. They [17] found the treated eyes showed a marked improvement in symptoms after 4 weeks of treatment.
In our study, all patients completed 24 months of follow-up, and none required additional medications, such as antihistamines, steroids, or mast cell stabilizers, to control disease activity. In the present study, 5 patients were excluded because they were intolerant to the severe burning sensation caused by the application of tacrolimus ointment. This effect may be associated with the activation of herpes simplex dendritic keratitis by the immunosuppressive properties of tacrolimus ointment.[16] However, none of our patients developed herpes simplex keratitis during the long-term follow-up period. The possibility of activation of herpes simplex dendritic keratitis by tacrolimus treatment requires further study. In a clinical study conducted by Sengoku et al.,[16] use of tacrolimus 0.1–1% eye drops achieved a dramatic improvement in the symptoms of patients with refractory VKC. In our study, 20 patients experienced initial mild conjunctival hyperemia (which subsides thereafter) for the first 3 days after initiation of treatment followed by relief of itching [Table 3]. When Miyazaki et al.[18] used tacrolimus 0.02% ointment to treat 5 patients with AKC and 1 patient with VKC who were refractory to conventional treatment; there was a marked improvement in symptoms within 2–4 weeks of treatment.
The symptoms of most of the patients in our study were relieved 4 weeks after beginning tacrolimus ointment treatment [Table 3]. Allergic symptoms recurred in all patients who attempted to discontinue tacrolimus. Consequently, they were kept on treatment for the entire follow-up period. Although a risk of T-cell lymphoma in patients using topical tacrolimus has been reported,[20] there is insufficient epidemiological evidence to determine if topical calcineurin inhibitors can cause malignancy.[21] Moreover, there is a scarcity of data regarding the optimal dose and duration of treatment. In fact, the blood concentration profiles of patients using tacrolimus 0.1% ointment were below quantifiable limits (0.5 ng/ml) in the majority of patients.[22] In our study, no malignancies occurred during the 2 years follow-up period, and the risk of developing malignancy after the application of topical tacrolimus 0.1% ointment is extremely low. Results from the available literature suggest that tacrolimus skin ointment is a safe and effective treatment for patients with refractory VKC.[20] The small sample size and the lack of randomization and a control group were the main limitations of the current study.
| Conclusion | | |
Tacrolimus, 0.1% ointment, was effective in controlling the clinical signs and symptoms of severe VKC refractory to topical antihistamine agents and topical cyclosporine. Our results demonstrate that tacrolimus is a promising alternative for the treatment of severe VKC. Further randomized controlled studies are required to evaluate the appropriate concentration and dosage of topical tacrolimus, as well as the long-term systemic safety of this medication.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Tabbara AK, El-Asrar A. Immunopathogenesis of ocular allergy. Progress in Allergy and Clinical Immunology. Seattle: Hogrefe and Huber; 1997. p. 381-5.  |
| 2. | Clark AF. Basic sciences in clinical glaucoma:Steroids, ocular hypertension, and glaucoma. J Glaucoma 1995;4:354-69. |
| 3. | Sacchetti M, Baiardini I, Lambiase A, Aronni S, Fassio O, Gramiccioni C, et al. Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire. Am J Ophthalmol 2007;144:557-63. |
| 4. | Bielory L. Allergic and immunologic disorders of the eye. Part II: Ocular allergy. J Allergy Clin Immunol 2000;106:1019-32. |
| 5. | Stahl JL, Barney NP. Ocular allergic disease. Curr Opin Allergy Clin Immunol 2004;4:455-9. |
| 6. | Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-55. |
| 7. | Sakuma S, Higashi Y, Sato N, Sasakawa T, Sengoku T, Ohkubo Y, et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol 2001;1:1219-26. |
| 8. | Zhai J, Gu J, Yuan J, Chen J. Tacrolimus in the treatment of ocular diseases. BioDrugs 2011;25:89-103. |
| 9. | Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256-65. |
| 10. | Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987;139:1797-803. [ PUBMED] |
| 11. | Ezeamuzie CI. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Int J Immunopharmacol 1996;18:263-70. |
| 12. | Tam PM, Young AL, Cheng LL, Lam PT. Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis – Case series. Br J Ophthalmol 2010;94:1405-6. [ PUBMED] |
| 13. | Mayer K, Reinhard T, Reis A, Böhringer D, Sundmacher R. FK 506 ointment 0.1% – A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin Monbl Augenheilkd 2001;218:733-6. |
| 14. | Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008;27:228-9. |
| 15. | Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005;24:417-20. |
| 16. | Sengoku T, Sakuma S, Satoh S, Kishi S, Ogawa T, Ohkubo Y, et al. Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models. Clin Exp Allergy 2003;33:1555-60. |
| 17. | Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010;26:165-74. |
| 18. | Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008;115:988-92.e5. |
| 19. | Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90:461-4. |
| 20. | Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother 2009;43:1956-63. |
| 21. | Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011;165:465-73. |
| 22. | Ebihara N, Ohashi Y, Fujishima H, Fukushima A, Nakagawa Y, Namba K, et al. Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension. Allergol Int 2012;61:275-82. |
[Table 1], [Table 2], [Table 3], [Table 4]
| This article has been cited by | | 1 |
Topical tacrolimus for the treatment of external eye inflammation in children |
|
| Andrea Bernales, Osvaldo Berger, Samer Hamada | | Expert Review of Ophthalmology. 2022; | | [Pubmed] | [DOI] | | | 2 |
Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: Recommendations From the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group |
|
| Jodhbir S. Mehta, Wei-Li Chen, Arthur C. K. Cheng, Le Xuan Cung, Ivo J. Dualan, Ramesh Kekunnaya, Nurliza Khaliddin, Tae-Im Kim, Douglas K. Lam, Seo Wei Leo, Florence Manurung, Nattaporn Tesavibul, Dominique Bremond-Gignac | | Frontiers in Medicine. 2022; 9 | | [Pubmed] | [DOI] | | | 3 |
Efficacy of medical treatments for vernal keratoconjunctivitis: A systematic review and meta-analysis |
|
| Inès Roumeau, Adrien Coutu, Valentin Navel, Bruno Pereira, Julien S. Baker, Frédéric Chiambaretta, Dominique Bremond-Gignac, Frédéric Dutheil | | Journal of Allergy and Clinical Immunology. 2021; 148(3): 822 | | [Pubmed] | [DOI] | | | 4 |
Experience With 0.1% Tacrolimus Eye Drop for Noninfectious, Non-necrotizing Anterior Scleritis |
|
| Hiroyuki Yazu, Dai Miyazaki, Hiroshi Fujishima | | Eye & Contact Lens: Science & Clinical Practice. 2021; 47(4): 185 | | [Pubmed] | [DOI] | | | 5 |
Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases |
|
| Hiroyuki Yazu, Kazumi Fukagawa, Eisuke Shimizu, Yasunori Sato, Hiroshi Fujishima | | Allergy, Asthma & Clinical Immunology. 2021; 17(1) | | [Pubmed] | [DOI] | | | 6 |
A Comparative Evaluation of Tacrolimus versus Steroids in the Treatment of Vernal Keratoconjunctivitis |
|
| Sharmiladevi Vadivelu, Prasanna Venkat, Rajesh Mimmithi, Sudarvizhi Arumugam, Sivakami Mohan | | Journal of Evidence Based Medicine and Healthcare. 2020; 7(9): 429 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
